Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

October 28, 2020

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 54 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Thanks, operator, and I appreciate everyone being here today as we go over Penumbra's earnings release for the third quarter of 2020. You can find the press release along with the financial table — it contains a GAAP to non-GAAP reconciliation — under the Investors tab on our website, www.penumbrainc.com. On this conference call, we'll be making forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, covering things like our financial performance, commercialization, clinical trials, regulatory status, quality, compliance and business trends. Because of certain risks and uncertainties, actual results might differ materially from what those forward-looking statements state or imply — including the risks referenced in our 10-Q for the quarter ended September 30, 2020, which we expect to file with the SEC on November 2, 2020, and those described in our 10-K for the year ended December 31, 2019, filed with the SEC on February 26, 2020. So we caution you not to place undue reliance on these forward-looking statements, and we encourage you to review our periodic filings with the SEC, including the 10-Q and 10-K just mentioned, for a fuller discussion of these factors and other risks that could affect our future results or the market price of our stock, including, but not limited to, how the COVID-19 pandemic impacts our business, results of operations and financial conditions. Penumbra disclaims any duty to update or revise our forward-looking statements as a result of new information, future events, developments or otherwise. On this call, with the exception of revenue, certain financial measures are presented on a non-GAAP basis. A reconciliation of GAAP to non-GAAP financial measures appears in our posted press release. We expect the prepared comments on today's call to run about 20 minutes. Adam Elsesser, Penumbra's Chairman and CEO, will give a business update. Maggie Yuen, our Chief Financial Officer, will then talk about our financial results for the quarter. And Jason Mills, our Executive Vice President of Strategy, will join Adam and Maggie for Q&A. With that, I'd like to hand the call over to Adam Elsesser.

Adam Elsesser

executive
#2

Thanks, Jee, and good afternoon, everyone. I appreciate you all being on Penumbra's call for the third quarter of 2020. For Q3, our total revenues came in at $151.1 million, which is up 8% compared to the same period last year on a reported basis and up 44% from the prior quarter. Turning to our biggest market, the United States, revenue was up 22% versus a year ago. Results from both the neuro and vascular franchises came in above what we had expected. Vascular revenue reached $75.2 million, rising 34% year over year and 62% quarter over quarter. Neuro revenue was $75.9 million, down 9% from a year earlier but up 29% sequentially. Going forward, both franchises remain strong, our innovation is picking up pace, and the growth opportunities in each are considerable over the coming years. In my prepared remarks today, I'll cover 5 topics. I'll talk about how COVID-19 affected Penumbra during this quarter and how it might affect us going forward. After that, I'll discuss the 4 growth engines at Penumbra: vascular, neuro, international expansion and the REAL System. To begin, let me take a few minutes to share our latest thinking on the pandemic. We got back to revenue growth this quarter even with the ongoing pressures from COVID-19. During the quarter, our primary concern regarding the pandemic was twofold: safeguarding our staff and significantly increasing production capability to meet growing demand. That challenge was successfully handled by our team, and as far as we know, there have been no instances of COVID-19 spreading between Penumbra employees. Rather than shrinking our workforce, we actually expanded it considerably during the quarter, and we made sure that employees in high-risk categories would still be paid even if they were unable to keep to a regular work schedule. Near-term margins have clearly been impacted by this effort, and Maggie will address that point in her remarks. Across numerous areas of the United States and abroad, we are all observing higher case counts and more hospitalizations tied to COVID. You can't help but be wary about the COVID risks still to come, especially soon. Alongside our efforts to fulfill product demand safely, the pandemic might hinder certain suppliers from delivering the materials we need to sustain strong growth in some products. And lastly, hospitals have done an amazing job working out how to manage a rising procedure schedule while still serving their COVID patients, yet we know that if COVID infections and hospitalizations speed up any further, that could put pressure on our hospital customers and also shape how patients view booking procedures. Let me move on to the four growth drivers we introduced during Penumbra's Investor Day back in December and have continued to talk about throughout the year. First up is our vascular franchise, which, as we've noted, will drive growth in both the near and medium term. The vascular numbers we posted this quarter make it obvious just how much room there is to serve a very large patient population. Compared with the stroke portion of our business, our vascular thrombectomy segment is larger and less penetrated, and it's ready for a fundamental change in how care is delivered. So it comes as no shock whatsoever — it truly doesn't shock us at all — that revenue from our vascular franchise now matches that of our neuro franchise, and it will probably expand to become the biggest business within the company during Q4. Our neuro business stands on very stable ground, but the vascular opportunity is just bigger and simpler to reach. In fact, every year in the United States, the count of peripheral thrombectomy patients on both the arterial and venous sides exceeds twice the count of stroke patients who can be treated. On top of that, vascular patients are already receiving treatment in hospitals from our existing customers, whether through lytics or surgical intervention. What Penumbra is bringing to this market through innovation is already changing patients' lives significantly, and down the road it might reshape the way most of these vascular patients receive care. On our last earnings call, I mentioned that the mid-July rollout of the new Lightning 12 system stood out as the best product launch ever for Penumbra. Our vascular growth, in my view, bears that out. Knowing how positively Lightning affects patients makes us feel even more motivated. Physicians' anecdotal responses about Lightning 12's performance have been excellent. We think that Lightning, alongside our bigger, highly torqueable catheter, has thus far demonstrated the correct blend of size and power to tackle the vast majority of target venous cases within the United States. Now the real effort begins. Across the coming several quarters, our team will be occupied steering through value analysis committees at hospitals so that Lightning becomes available to a wide set of customers in the United States. After that, we anticipate bringing Lightning 12 into key international markets during the second half of 2021. With Lightning 12, we are only beginning to scratch the market's surface, and its effect on our vascular business remains nascent. At the same time, we feel just as strongly about the money we're putting into additional innovation and clinical evidence, and our view is that together these will move the Indigo power aspiration paradigm forward worldwide. In particular, we recently secured FDA clearance for the Lightning 7 system, and we will begin our U.S. launch in early 2021 as soon as we have adequate inventory. Like Lightning 12, Lightning 7 makes use of our next-generation hypotube-based torqueable catheter technology. We also think Lightning 7 could prove to be a very valuable instrument in assisting physicians with the removal of arterial clot. Lastly, our vascular embolization business likewise enjoyed its strongest quarter on record, despite only partial benefit from a rebound in certain elective cases that had been postponed from Q2 into Q3. Although we can't say for certain, we figure that advantage may have reached $2.5 million during the quarter, and the fact that vascular embolization delivered a record quarter even without that estimated gain speaks volumes about our vascular team and our distinctive products. Now on to our neuro franchise, where we felt good about how the business improved as we came out of the second quarter. Sequentially, we achieved double-digit growth in ischemic stroke, neuro embolization and access. Ahead of covering our neuro pipeline, I'd like to address JET 7 XTRA FLEX. In recent months, the investment community has raised numerous questions regarding this product, as well as the notification letter that went out to physicians at July's close. To begin, I want to state plainly that among all trackable reperfusion catheters we've ever introduced, JET 7 XTRA FLEX stands as the most advanced; the significant role it played in our Q3 results, which I'll get to shortly, confirms this. Next, our physician customers are something we feel great appreciation for. They collaborated with the Penumbra team, devoting their time to getting reacquainted with the key guidance for JET 7 XTRA FLEX and applying it in practice, so they could treat their stroke patients both safely and effectively. Because of the inquiries that came up during this quarter, we believe it's worthwhile to provide additional specifics in 2 areas. To start, U.S. revenue for JET 7 XTRA FLEX during the third quarter came to within $400,000 of the strongest sales quarter this product has ever had.

Adam Elsesser

executive
#3

And then second, and I think this is even more significant, we have no knowledge of any additional reports — whether they came to the company or showed up in the MAUDE database — that were tied to the notification and involved incidents taking place after the notification date. Keep in mind that the neurovascular field has always featured, and in all likelihood will keep featuring, a substantial and fierce level of competition. As I said openly at investor conferences during September, rival manufacturers are leveraging our revised instructions for use competitively to persuade physicians to give their offerings a try, and that focused push prompted some customers to trial those products. Thanks to how exceptionally JET 7 XTRA FLEX performs, the great majority of those customers have returned to JET 7 XTRA FLEX. Even so, just as we have said consistently before, we anticipate that rivalry in the neurovascular space will stay fierce. And our top-tier commercial organization will keep ensuring our customers understand what our products are worth. Going forward, Penumbra keeps designing and developing products for treating stroke patients. We just finished our first cases with the BMX96 catheter, which works alongside JET 7 XTRA FLEX and upcoming products to make a faster, more sophisticated stroke procedure possible; we hold a very positive outlook on what BMX96 will bring to physicians and their stroke patients over the coming quarters; we have confidence in our existing lineup of neuro market leaders, with JET 7 XTRA FLEX at the front, and we are thrilled to bring yet another new paradigm to physicians who treat stroke during 2021. Now allow me to turn to our business outside the U.S. In the third quarter, our international business bounced back strongly, returning entirely to Q1 2020 levels across most geographies. Leaving out Japan, our total international revenues rose 2% versus the prior year and 58% compared with the prior quarter. Japan clearly took a hit this quarter from the halt in the JET 7 XTRA FLEX launch that I disclosed publicly in early September at an investor conference. We have heard that our distributor partner intends to resume that launch later this quarter, once Japan approves the modifications to the IFU. Japan could become a sizable growth driver for Penumbra going forward, in both absolute and relative terms, as we introduce new products — neuro as well as vascular — into Japan and expand from the fairly modest revenue run rate we have there at present. Let me spend a moment discussing our approach to boosting our growth profile in markets outside the U.S. With the overall growth of our business continuing to tilt toward vascular, we are also reshaping our international sales capacity. To illustrate, we're setting up specialized sales groups for vascular and neuro in Europe, since we want to speed up how quickly patients can access our novel offerings across both franchises. On top of that, we keep assessing inventive go-to-market approaches in select major regions, aiming to boost our capacity to deliver our latest products there. Let me now move on to the REAL System. As mentioned before, the pandemic compelled us to push back the first launch of the REAL System, and only recently have we begun delivering the earliest units to rehabilitation facilities. What patients have told us so far validates both our dedication and the significant financial commitments behind this product. Take, for instance, a woman in the Southeast who suffered a stroke more than 12 months ago and spent 12 months in conventional rehab. Her progress through conventional rehab stalled fast, leaving her with just minimal arm function. After that tough 12 months, she began utilizing the REAL System. Within roughly 1 month of usage, she recovered functional movement in her arm. Stories like this one, and numerous others, are deeply moving and drive the whole team to work tirelessly on the upcoming stages of the REAL System—specifically telerehab, home use, and further uses aimed at other major serious medical conditions. The vast array of medical conditions that our REAL System can address constitutes, by a wide margin, the biggest overall market opportunity Penumbra has ever pursued, and we are tremendously excited about how many individuals we can assist. We'll share publicly the progress we're achieving in both the REAL product lineup and business model during the first half of 2021. Lastly, 2020 has been a difficult 12 months for our nation and the globe, given the pandemic along with social unrest and unpredictability. Amid these trying periods, the Penumbra team has stepped up and propelled the company to our present achievements, while simultaneously positioning us better than ever for ongoing expansion ahead. How individuals behave and perform when times are tough reveals their true measure, and I feel immensely privileged to collaborate with this group that has demonstrated its integrity, expertise, and modesty. I'm delighted to report that the Penumbra team has proven equal to the task and risen to meet it. I'll now hand the call over to Maggie.

Maggie Yuen

executive
#4

Thanks, Adam. Good afternoon, everyone. In today's remarks, I'll go over the financial results for the third quarter of 2020. More information will be included in our quarterly reports on Form 10-Q, which we plan to file with the SEC on November 2, 2020. For the third quarter that ended September 30, 2020, total revenues came to $151.1 million, which was up 8.3% as reported and up 7.7% in constant currency versus the third quarter of 2019. Our sales mix by geography during the quarter was 73% U.S. and 27% international. On a sequential basis, U.S. and international each grew 41% and 53%, respectively, compared with Q2 2020. Revenue from our vascular business reached $75.2 million in the third quarter of 2020, rising 34% as reported and 33% in constant currency; during the quarter, vascular results were fueled by expansion in both our thrombectomy and embolization franchises, helped by the launch of Lightning 12 and by embolization case recovery from the prior quarter. Revenue from our neuro business was $75.9 million in the third quarter of 2020, down 9% as reported and down 10% in constant currency versus the same period a year earlier. Our U.S. neuro business rose 15% as reported on a sequential basis, powered by growth across all neuro businesses. Beyond that, our international neuro franchise experienced better distributor orders; and total neuro international revenue climbed 57% sequentially while falling 18% compared with Q3 2019, due to the timing of the JET 7 XTRA FLEX launch in Japan. Gross margin for the quarter was 60% of revenue, versus 69% of revenue in the same quarter last year. The decline from Q3 2019 comes from 3 components. Protecting our employees and satisfying demand are our top priorities. In pursuing that, we've made incremental investment in COVID-19-related safety measures, including trade-offs in productivity and capacity. Second, to back new product launches and satisfy rising demand in a less efficient manufacturing environment, we've sped up investment in direct labor hires and production support so we can scale up production at both our Alameda and Roseville manufacturing facilities. And finally, unabsorbed manufacturing variances from Q2 also hurt our gross margin as inventory moved through in the third quarter. With the current demand trend, we expect gross margin to improve gradually over coming quarters, and we believe investment in product, resources and infrastructure will drive further margin expansion in the future. During the quarter, we incurred onetime nonrecurring personnel-related expenditures of $20.7 million tied to the launch of Lightning 12. The following financial metrics will reflect non-GAAP financial results, excluding those nonrecurring expenditures. Adjusted operating expenses for the quarter were $90.4 million, or 60% of revenue, compared with $83 million, or 60% of revenue, a year ago, which represents 9.5% sequential growth versus the second quarter of 2020. As revenue momentum improved, we rebalanced some temporary cost control measures that we had put in place in the wake of COVID. During the quarter, we likewise expanded hiring tied to volume along with associated efforts, and we keep directing strategic funding toward several fresh product development possibilities, at a level comparable to what we saw in Q2 of 2020. Adjusted operating income for the quarter came in at $0.5 million, versus operating income of $13 million during the identical stretch a year earlier. Moving on to cash flow and the balance sheet: accounts receivable rose by $15 million, while net inventory grew by $8 million relative to the second quarter of 2020. Working capital figures aligned with the patterns in volume. We closed out the third quarter of 2020 holding $269 million across cash, cash equivalents, and marketable securities, with zero debt. Last, back in early April, we pulled our 2020 guidance as the COVID-19 pandemic began; we aren't officially restoring guidance right now given the uncertainty arising from the present rise in COVID-19 cases and hospitalizations. Still, we do wish to note that absent any additional adverse COVID effects on the medical device sector going forward from here, we'd feel at ease seeing our fourth quarter revenue land at or a bit above the record levels we hit in the third quarter. At this point, I'd like to hand the call back over to Adam for his closing remarks.

Adam Elsesser

executive
#5

Thanks, Maggie. During Q3, Penumbra brought in more money than in any other quarter since the company began. That speaks to the caliber of our team and the way we work, to what we build, and to a remarkable knack for never standing still — and above all, it speaks to those we serve. I want to recognize the doctors, nurses, and other medical professionals, whose remarkable commitment shows itself daily yet has stood out in particular across the last few months. Facing tremendous difficulties in the battle against COVID-19, these heroes pushed themselves even harder to care for a growing number of patients dealing with neurovascular and peripheral vascular disease. My thanks to each of you for your remarkable efforts. At this point, we'd like to take questions from the call. Operator, please go ahead.

Larry Biegelsen

analyst
#6

Nice quarter — congrats on that. Adam, on the previous call you said Lightning 12 would be the company's most successful launch ever, and you sure weren't joking. So I'd like to begin right there; regarding U.S. vascular, did anything onetime show up in Q3? Could you discuss the mix a bit versus the volume benefit? And what's the right way to think about this sales level moving forward?

Adam Elsesser

executive
#7

Yeah. Larry, first off, thanks for asking. As you recall, we kicked off this product's launch — or its introduction — roughly 2 weeks into the quarter. That left us 10 weeks within the quarter to get it done. So most of what we're seeing is simply cases being performed. In-stocking and similar items account for very little. That kind of thing, as you know, requires considerable time and, especially these days, appears to take even longer. So for Lightning, the bulk of this increase is essentially case usage. And like I mentioned last quarter, the reaction has come very easily and quickly — after a single case, we've watched it happen again and again — it's simply been that extraordinary. It just performs; it's the right blend of size and power, as I've hinted at, so you can safely remove clot from DVT and many other cases. So we're quite optimistic. Our expectations for this product were high; and the market has so far responded well to it. But like I hinted at in my prepared remarks, the real work begins now. We must get through the Value Analysis Committee, and all of that appears to take a bit longer than it once did. So that will require a number of quarters. Yet over the long term, we believe we're on an excellent path with this product to help a significant number of people.

Larry Biegelsen

analyst
#8

That sounds excellent. Now Adam, regarding the international side, you brought up international upfront during your prepared comments. Should we anticipate sequential improvement there in Q4? I also wanted to slip in one more thing, Adam. At the December analyst meeting, you set a target of $1 billion in sales for 2023. Does that still stand? Or do we need to consider that it might get delayed by a year as a result of COVID?

Adam Elsesser

executive
#9

Certainly. So, addressing your first point, assuming no fresh COVID developments — and I want to be clear, I have no particular information here. This isn't a hint of anything to come — our October has begun much like any other October and like the preceding quarter, in an ordinary way; so please don't interpret anything from that, but when you get up this morning and see the headlines saying France, Germany, Italy, and Spain are all entering lockdown, and your question concerned international. So we simply don't know. That said, absent those problems, if no such new effects arise, then yes, we do anticipate that international will keep bouncing back, just as you described. As for your other question, we have complete confidence that we'll keep expanding and hit that target. The precise quarter-by-quarter timing, once again, since right now we're confronting headline upon headline about COVID, causes me just a bit of hesitation about locking in a specific point in time; however, I believe this quarter demonstrates that our business remains as robust as it has ever been, and that we're highly confident we will not merely arrive at the $1 billion mark, but also move into plus territory within a suitable time frame.

Bill Plovanic

analyst
#10

Let me dig a bit deeper into what Larry was asking about. Looking specifically at the peripheral space — you brought up DVT, but when it comes to DVT compared with PE and the other segments, where is most of the expansion actually coming from? Then I want to follow up on the international side as well. During the opening remarks, you talked about certain adjustments to that international setup, essentially dividing the sales teams. Could that be done fairly fast, so it's ready by the end of this year and then you enter '21 running? Or is it more of a gradual shift in that channel that we'll observe as time goes on?

Adam Elsesser

executive
#11

Yes, that's a good question, Bill. Regarding the mix, it's genuinely been spread across every segment. There's no single area we could point to, which honestly isn't a shock, but it gives us a lot of confidence that among those areas we've truly located what you might call the ideal fit, or the sweet spot. So we feel especially positive about it; and keep in mind that this is — we're discussing Lightning 12 as the new product; but the remainder of our portfolio on the arterial side and coronary side has also performed quite well and keeps expanding separately from this launch, though I certainly don't want to diminish this excellent product launch. When it comes to the structure in Europe, those first changes were implemented only recently. Seeing the impact of them will take somewhat longer; we built the management structure, and now there's some hiring left to do — not much, but some. And beyond that, Lightning hasn't yet been approved in — or cleared in Europe with the CE mark. So once that comes through, it will also fuel growth; and I referenced that in my prepared remarks.

Bill Plovanic

analyst
#12

All right, and maybe a follow-up question from me. Regarding that $20.7 million tied to one-time charges involving Lightning, could you break down a bit more precisely what those are for?

Adam Elsesser

executive
#13

Sure. Without going somewhere that might put us at a competitive disadvantage, the largest portion of it stemmed from development-related efforts that were wrapped into an arrangement which made it possible for Lightning to come into being at all. That is the reason it is being treated as a one-time charge.

Bob Marcus

analyst
#14

Congratulations on a strong quarter. Adam, I realize questions about REAL VR don't come your way very often, but reimbursement rules have shifted, and you called that out in the script. How should folks be thinking about this across, say, the coming 2 to 4 years? Could it begin adding to revenue toward the earlier part of that window? Or is this still an exciting opportunity that sits further out?

Adam Elsesser

executive
#15

Yes. I appreciate the question about REAL. Regarding REAL — the precise timing of the launch, the business model, and everything else, we'll address more publicly, as I mentioned during the first half of next year; however, if you're framing the near term, or perhaps the midterm, as the initial 2 years rather than 4 years beyond that, the answer is absolutely that it can begin contributing. What matters most is something we want everyone to grasp: as we've developed the product and expanded into greater telerehab and additional medical conditions beyond the more conventional neuro rehab, the TAM, so to speak, has grown quite dramatically. And once more, we'll present that in greater depth when we reveal this publicly. Yet it has genuinely turned this into an enormous opportunity. So we intend to be cautious. We're going to be — essentially do it properly. And once everything is in order and the product is ready, we can hardly wait to share it with everyone.

Bob Marcus

analyst
#16

Great. And perhaps one brief follow-up. Your rival in peripheral aspiration carries a steeper price than yours, according to what I think you've said and a few of the checks we've run. How ought we to view U.S. peripheral performance in the third quarter when it comes to price against volume? If you'd rather not give us specifics, any qualitative color would be genuinely useful in pointing us the right way.

Adam Elsesser

executive
#17

Yes. I'd call that a completely reasonable question. Volume, rather than price, accounts for the overwhelming bulk of this. As you're aware, there's a modest price increase, which gets partly offset by reduced use of the separator in the case. So price does play a small role. But I'd firmly say the great majority of these cases are new ones we wouldn't have necessarily captured. Mainly — I mean, this field is big. Like I've mentioned, the largest competitor is physicians employing catheter-directed lysis or tPA, and that's where we directed our efforts and time; and as I noted in my prepared remarks, at this particular moment, this area is ripe for a paradigm change; and we discovered a very willing set of physicians, so to speak, a sizable group ready to give it a try and who saw its value right away. So to answer your question, it's largely volume and largely patients we hadn't been treating previously.

Bob Hopkins

analyst
#18

Just a few quick follow-ups. A quick one first; during Q2, you brought up destocking abroad. Did that play a role in this quarter? And is it basically finished now?

Adam Elsesser

executive
#19

Yeah. I'd say it's — the bulk of that has returned, and we didn't truly view it as a factor. We didn't mention it by name this quarter. So yes, I'd go along with that assessment.

Bob Hopkins

analyst
#20

Then I'm also wondering — thanks for providing that U.S. neuro figure. What I'd like to know is, regarding your revenues from U.S. ischemic stroke, would you say the — what happened during the quarter was pretty typical of how the wider market performed?

Adam Elsesser

executive
#21

Honestly, I can't say, since many of the competitors haven't — the manufacturers haven't put out their reports yet. My guess would be, and I believe I made a point of stating this, that it could be somewhat below the wider market, given that all that competitive trialing was taking place. I can't be certain of that. As you're aware, our neuro franchise had a noisy quarter with a great deal of competitive activity. That's not something, once again, that's unfamiliar to us; but I wouldn't — there's no way for me to respond to that until those figures come in. What it does indicate to me, however, over the long term and where — how we did and how our customers reacted over the long term is genuinely encouraging. Despite all that noise and effort, the overwhelming majority of our customers have demonstrated that they value this product. And I believe our business is quite solid looking ahead.

Bob Hopkins

analyst
#22

Then, the final item I’d really like you to address very briefly is the broader matter of competition throughout the business. Since roughly 3 or 4 years back, folks became quite anxious regarding rivalry in neuro, and many efforts there fizzled out early, yet your team has essentially stayed highly competitive during that entire period. So concern about competitors in neuro arrived far too soon. I was hoping you might compare and contrast the competitive landscape you foresee emerging in vascular, from a number of businesses launching new offerings, against what happened in neuro. Would you describe it as a comparable situation? Or do you believe there are distinctions we ought to keep in mind when assessing competition in vascular relative to neuro?

Adam Elsesser

executive
#23

Yes. I truly — without intending any offense toward anyone involved in this area, they are excellent producers, collectively, genuinely attempting to do what’s right, namely advancing the discipline toward a point where extracting clot from the body becomes a far more sensible and superior intervention than what exists now. And I hold them in high regard. Having said that, I don’t believe we devote much thought to rivalry here, the manner in which we have consistently viewed it in neuro. Within neuro, it has always been intense. We came into this space behind those businesses. In this case, the situation differs somewhat for the majority of them. And the opportunity is simply so vast, and all of us — each of our mechanisms differs somewhat, we hold differing perspectives. So we truly don’t perceive competition within an identical structure at all; honestly, I’d be taken aback if the other businesses didn’t express the identical view; it lacks that same kind of response and quality that neuro possesses. And it is simply so much bigger. When you examine neuro, there are, what is it, 10 businesses presently operating in neurovascular, each pursuing a comparatively limited pool of procedures. That’s wonderful, and we take real pride in our efforts and in what we’ll accomplish moving forward, since we believe we can keep competing extremely effectively. Yet it simply isn’t equivalent to the vascular chance. When you consider it, Bob, building our stroke operation to its current position required 13 years, while getting our neuro — or rather our vascular operation to match that scale took 5 years. I suspect that reveals everything necessary regarding how we view what lies ahead for this area.

Joanne Wuensch

analyst
#24

I've got two things to ask, and I'll just put them out there right away. The first concerns our R&D spending. That figure has gone up a lot over the past 2 quarters, and what I want to know is whether you view that as the run rate going forward, or if, because of a few of the launches that you've managed to get out the door successfully, it settles back to something more normalized when you look at it in dollar terms. Then for my second question, it's somewhat broader and relates to the neuro market. Whenever we speak with physicians, we continue to hear accounts of how the count of ischemic stroke patients is below where it stood last year, in a pre-COVID environment. Is that something you're observing? Or is it simply the doctor I happen to be picking? And if it is real, what's your explanation for it?

Adam Elsesser

executive
#25

Thanks, Joanne. Maggie is going to take the first question, and after that I'll handle the second one.

Maggie Yuen

executive
#26

Absolutely. Joanne, I appreciate you raising that. When it comes to operating expense, once that one-time, nonrecurring charge we called out is removed, that $90 million figure gives us a sensible baseline for thinking about how our underlying operating expense moves alongside volume going forward. As you may recall, beginning with the prior quarter, we increased our R&D investment, tied specifically to several new development programs, and that step-up will probably persist over the next few quarters.

Adam Elsesser

executive
#27

Now, regarding the neuro question — it's a genuinely perceptive one, and the picture is somewhat mixed. Some of our customers are definitely experiencing a notable rise in stroke patients, at minimum in the short run, from around the close of Q1 through Q2. Meanwhile, certain other customers who have capacity, who are able to treat patients, have actually recorded a modest decline. Honestly, I'm not sure how to frame that beyond the genuine difficulty in the stroke arena that we've discussed for the past 5.5 years — namely, getting patients to the proper location. And clearly, there's zero evidence that fewer strokes are occurring. So the issue becomes: is this a matter of patient flow, and is something tied to this particular point in time and COVID altering that flow, such that patients aren't being transferred the way they previously were? That answer might hold in those instances; it definitely isn't universal, and other hospitals have recorded a rise, but among those you may have spoken with and those we're aware of, it just — it, I believe, brings that difficulty into focus; it's also worth noting that this difficulty is absent in the vascular business, which is likely the reason we see it continuing to expand and will continue to, since those patients are invariably already in the place they ought to be. So obviously, we aren't throwing in the towel. We've made substantial progress in stroke, and our outlook on the future of our stroke business is extremely positive. But I believe that difficulty will remain indefinitely when it comes to getting patients to the proper location. And there has to be something about this particular point in time with COVID that is rendering that difficult, at least for the hospitals I'm aware of as opposed to the ones you're speaking with.

Margaret Kaczor

analyst
#28

Perhaps my first question just builds on what you said regarding the batch for Lightning 12. Clearly, even with the hold-ups, your growth remains extremely rapid. Yet what effect might this have on adoption across the coming 3 to 5 quarters compared with what you previously anticipated? And honestly, is a fairly swift catch-up possible, or not?

Adam Elsesser

executive
#29

The way we look at it — I mean, this product, like I mentioned, I mentioned it during the last quarter, just a few weeks after launch, is the finest product we have ever brought to market; the rise is truly remarkable, and we — it truly falls to us and the hospital systems to now move this through the process. And that process is never simple, as you're aware, when going through the Value Analysis Committee at hospitals. Certain hospitals have made it even more difficult because — given the financial strain on hospitals' systems this year, they have imposed outright bans on new products. One system did exactly that, yet we managed to secure a quick waiver thanks to the value this product delivered. So really it's simply that effort. Timing is hard to forecast, except to recognize that it lies ahead of us, and it will not be linear or straightforward. With that said, the product itself, in my view, is performing in a manner that truly can — truly reach so many of these patients who currently receive catheter directed lysis rather than mechanical thrombectomy, and that, I believe, genuinely provides us with a great deal of confidence in this.

Margaret Kaczor

analyst
#30

All right. That appears to be somewhat beyond what you can influence, though clearly you are making every effort to handle things as well as possible. With luck, conditions improve in 2021.

Adam Elsesser

executive
#31

Indeed. Indeed.

Margaret Kaczor

analyst
#32

Next, I'd like to dig a bit deeper into what was said regarding how we performed in Q4. Obviously, a great deal remains up in the air, though I believe you provided some guidance that doesn't factor in COVID sticking around. Honestly, it's somewhat unexpected to me that you don't anticipate more sequential momentum. That's what we observed 12 months ago, and in periods prior to that; so perhaps you could take us through how those forces work. What was the process behind arriving at those figures? Also, is there anything you can share about shutdowns in Europe — have they affected things so far?

Adam Elsesser

executive
#33

Yes. That's a completely reasonable thing to ask. To begin, let's all remember that formal guidance was not something we provided; that point was made very explicitly. Our aim was to offer a kind of qualitative framework so you could think through how our business looks in Q4. We took care to examine what occurred this quarter, the one before it, and what the underlying trends are, and those trends are favorable; even so, we did point out some carryover — a couple of million dollars, a bit more within our peripheral embolization business — which clearly won't be repeated in Q4. So that is what — produced those figures for us. Once more, provided conditions don't deteriorate, we believe that figure can be reached. Should conditions worsen, we have no way of knowing. And clearly it's intensifying; just this morning, all of us got up to news, and the market responded to that news. So that part is unknown. But let me ensure it's clear to everyone that beyond Q4; as a company, we're in the best position we have ever occupied. I hope you caught me saying that. And we sense that while we steer through COVID, in addition, we also hold the strongest portfolio, we've had our products, and once COVID's unpredictability is behind us, we believe substantial growth lies ahead; we're in genuinely strong shape. Even with COVID, we're demonstrating that we can perform quite well; nevertheless, we're staying conservative regarding those figures for that reason.

Ryan Zimmerman

analyst
#34

Adam, we've come across some early clinical findings indicating a rise in clotting tied to COVID. And after talking with a few vascular surgeons, they've definitely backed up that they're treating a larger volume of patients because of it. So I'd like to know whether you can address what the business has shown you that either backs up or contradicts this pattern, and whether that might serve as an added tailwind across the next several quarters while doctors handle those growing case counts? Is it reasonable to think these patients would sit on top of the roughly 400,000 figure you mentioned earlier?

Adam Elsesser

executive
#35

Yes. Ryan, that's an excellent question. And yes is the answer. Those figures we've cited regarding arterial and venous cases — 430,000 treated through some method, whether surgical intervention, catheter directed lysis, or simply plain lytics — those predate COVID; so without a doubt, that figure could rise in the near term. What we don't believe is that these — these COVID patients are the only ones we're treating at present, where they're merely enlarging that pool temporarily. And one factor that I think genuinely makes us hopeful about this is that when people who have previously used catheter directed lysis in particular and have given Lightning 12 a try, their response is, "Oh, well, with this product, we might just convert." And so in that scenario, if there are additional patients in the near term whom they can treat, that's wonderful. But it truly speaks to the bigger market we're only beginning to reach. So I mean, we have quite a distance to cover before we're treating 430,000 patients in the U.S. We remain in the single digits for penetration. So plenty of work lies ahead of us. But yes, you're correct. It does enlarge the pool somewhat in the near term.

Ryan Zimmerman

analyst
#36

All right, thank you for that response. Then I have one more question, this one directed at Maggie. Earlier in this call, we discussed Lightning during the quarter, and considering the premium price you're commanding for Lightning relative to reduced separator utilization — Maggie, I'd like to know whether you could weigh in on how this might affect margins, or might not, for the company, as Lightning keeps being among the main growth engines within the vascular business.

Maggie Yuen

executive
#37

Yes, when it comes to the margin — the gross margin effect — Lightning might contribute a very small accretive benefit to our margin. However, as I explained regarding how our margin performed, the effect on our gross margin during this quarter tied specifically to price and mix is certainly not a material one.

Jee Hamlyn-Harris

executive
#38

Thank you, operator. Our management team and I want to express our appreciation once more for everyone being here today and for the attention you've shown toward Penumbra. We're eager to bring you up to speed during this fourth quarter call.

Operator

operator
#39

Everyone, that brings us to the end of today's conference call. We appreciate you joining us, and you're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.